Canadian Treatments for COVID-19 (CATCO)

CATCO is a multi-centre, adaptive, randomized, open-label, controlled clinical trial conducted to learn about the safety and efficacy of various therapeutics for the treatment of COVID-19 in hospitalized patients. CATCO is conducted in conjunction with the World Health Organization’s (WHO) SOLIDARITY Trial PLUS, in collaboration with countries around the world.

The overall objective of the study is to evaluate the clinical effectiveness of the study drugs, relative to the control arm (standard of care), in patients hospitalized with COVID-19.

National principal investigator: Dr. Srinivas Murthy, University of British Columbia

Provincial (Ontario) and Sunnybrook Hospital principal investigator: Dr. Rob Fowler

You may be eligible to participate if you:

• Are 18 years of age or older
• Have a laboratory confirmed COVID-19 infection
• Are hospitalized at a participating study site
• It is your first hospital admission for acute COVID-19

Participants will:

• Be randomized to one of the treatment groups, while hospitalized
• Have blood work collected during the study
• Be followed-up with periodically for 6 months; some follow-ups may occur over the phone after you are discharged from hospital

If you are admitted to Sunnybrook Hospital and interested in participating in this trial or want to learn more information, please talk to your doctor at Sunnybrook Hospital about the CATCO trial.